Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019
01:07pm, Friday, 28'th Feb 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2019 and highlighted recent company events including several accomplishments
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
12:28pm, Friday, 28'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020
02:00pm, Tuesday, 25'th Feb 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 40th Annual Health Care Conference in Boston, on Tu
-$0.35 EPS Expected for GlycoMimetics Inc (NASDAQ:GLYC) This Quarter
06:54pm, Monday, 17'th Feb 2020
Equities analysts predict that GlycoMimetics Inc (NASDAQ:GLYC) will report earnings of ($0.35) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued es
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.
08:35pm, Tuesday, 11'th Feb 2020
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital GLYC;PFE
04:48pm, Tuesday, 11'th Feb 2020
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital Roth Capital GLYC PFE
Pfizer notifies GlycoMimetics of termination of license agreement GLYC;PFE
04:39pm, Tuesday, 11'th Feb 2020
Pfizer notifies GlycoMimetics of termination of license agreement GLYC PFE
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN )
Trials flops see Pfizer cut GylcoMimetics pact, Merck ax KalVista research deal
09:19am, Tuesday, 11'th Feb 2020
Two Big Pharmas have decided to walk away from two small biotech deals after disappointing trial results: Pfizer from GlycoMimetics and Merck from KalVista Pharmaceuticals.
Wall Street Pros: These 3 Stocks Can Double Next Year
03:40pm, Thursday, 06'th Feb 2020
Let’s not complicate matters. Broken down into the most basic elements, it’s all very simple: investors want to put their hard earned cash in a place where they will return to after a period of ti
GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations
02:53pm, Tuesday, 04'th Feb 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced several achievements for its GMI-1359 development program, including the issuance of a new patent and key designations granted by the U.S. Food and D
Risk Premia Forecasts: Major Asset Classes | 4 February 2020
12:00am, Tuesday, 04'th Feb 2020
Stocks Analysis by James Picerno covering: Russell 3000 Total Return. Read James Picerno's latest article on Investing.com
First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
02:00pm, Thursday, 30'th Jan 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics' novel GMI-1359 drug c
